[27]
Again, paragraph 21(b) of the statement of claim, which sets out that the
Pneumocort
trademark is not distinctive, is, given the factual material which precedes it and the sections of the
Trade-marks Act
which follow it, sufficient from the point of view of explaining the nature of the case to be met, to inform the defendant that, from the plaintiffs' point of view, there has been and may in future be confusion between the trademarks and a resulting lack of distinctiveness.